Company News
Spruce Biosciences Up 3.2% on MPS IIIB
Spruce Biosciences shares rose 3.2% in after‑hours trading after presenting six‑year data on its tralesinidase alfa therapy for MPS IIIB.
In a 22‑patient study, TA‑ERT normalized CSF heparan sulfate l
